Patents by Inventor Hyo Jung Choi

Hyo Jung Choi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11975076
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: May 7, 2024
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Publication number: 20240130230
    Abstract: The present disclosure relates to a plurality of host materials, organic electroluminescent compounds, and organic electroluminescent devices comprising the same. By comprising specific combinations of compounds according to the present disclosure as the plurality of host materials or by comprising a compound according to the present disclosure, it is possible to provide organic electroluminescent devices having improved lifespan characteristics compared to conventional organic electroluminescent devices.
    Type: Application
    Filed: August 8, 2023
    Publication date: April 18, 2024
    Inventors: Doo-Hyeon MOON, DaiKyu KIM, Hyo-Jung LEE, Yea-Mi SONG, Kyoung-Jin PARK, Hyun-Ju KANG, Ga-Won LEE, Mi-Ja LEE, Kyung-Hoon CHOI
  • Publication number: 20240074258
    Abstract: An electronic device includes a display device, which may be fabricated using a described method. The display device includes a glass substrate including a first surface, a second surface opposite the first surface, and a side surface between the first surface and the second surface, an outermost structure on the first surface of the glass substrate and located adjacent to an edge of one side of the glass substrate, and a display area including a plurality of light emitting areas on the first surface of the glass substrate and located farther from the edge of the one side of the glass substrate than the outermost structure is. A minimum distance from the side surface of the glass substrate to the outermost structure is equal to 130 ?m or less.
    Type: Application
    Filed: May 5, 2023
    Publication date: February 29, 2024
    Inventors: Wan Jung KIM, Dong Jo KIM, Sun Hwa KIM, Young Ji KIM, Chang Sik KIM, Kyung Ah NAM, Hyo Young MUN, Yong Seung PARK, Yi Seul UM, Dae Sang YUN, Kwan Hee LEE, So Young LEE, Young Hoon LEE, Young Seo CHOI, Sun Young KIM, Ji Won SOHN, Do Young LEE, Seung Hoon LEE
  • Publication number: 20230270868
    Abstract: The present invention relates to a pyrrolobenzodiazepine dimer prodrug and a ligand-linker conjugate compound thereof, a composition containing these, and therapeutic use thereof particularly as an anticancer drug. The stability of the compounds themselves and the stability thereof in plasma are excellent and the compounds are advantageous in terms of manifestation of toxicity, and thus the compounds are industrially useful in that it is possible to target proliferative diseases such as cancer, to perform a specific treatment, to maximize the drug efficacy, and to minimize the occurrence of side effects.
    Type: Application
    Filed: February 24, 2023
    Publication date: August 31, 2023
    Inventors: Ho Young Song, Sung Min Kim, Hyoungrae Kim, Kyung Eun Park, Chul-Woong Chung, Yun-Hee Park, Hyo Jung Choi, Su In Lee, Juyuel Baek, Hyeun Joung Lee, Ju Young Lee, Ji Hye Oh, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim
  • Patent number: 11654197
    Abstract: The present disclosure relates to pyrrolobenzodiazepine dimer prodrugs and ligand-linker conjugates thereof. The present disclosure also relates to compositions and uses of said prodrugs and conjugates.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: May 23, 2023
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Ho Young Song, Sung Min Kim, Hyoungrae Kim, Kyung Eun Park, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Su In Lee, Juyuel Baek, Hyeun Joung Lee, Ju Young Lee, Ji Hye Oh, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim
  • Patent number: 11473079
    Abstract: The present invention relates to a method for prenatal diagnosis using digital PCR, and more particularly to a method for providing information for diagnosis of chromosomal aneuploidy in a fetus, comprising: (a) extracting DNAs from pregnant woman's blood; (b) classifying the DNAs according to size to obtain DNAs having a size of 1,000 bp or less; (c) performing digital PCR using the obtained DNAs of step (b), for a control gene located on a chromosome not associated with chromosomal aneuploidy and a target gene located on a chromosome associated with chromosomal aneuploidy; (d) calculating a ratio of a quantitative digital PCR value of the target gene to a quantitative digital PCR value of the control gene; and (e) determining that when the ratio calculated in step (d) is 0.70-1.14, a chromosome number of the fetus is normal.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 18, 2022
    Assignee: BIOCORE CO., LTD.
    Inventors: Seung Yong Hwang, Moon Ju Oh, Seung Jun Kim, Jong Pil Youn, Ji Hoon Kim, Seung Yong Lee, Jeong Jin Ahn, Joon Soo Park, Hyo Jung Choi
  • Patent number: 11413353
    Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: August 16, 2022
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Publication number: 20220218840
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.
    Type: Application
    Filed: November 12, 2021
    Publication date: July 14, 2022
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Publication number: 20220218830
    Abstract: The present disclosure relates to pyrrolobenzodiazepine dimer prodrugs and ligand-linker conjugates thereof. The present disclosure also relates to compositions and uses of said prodrugs and conjugates.
    Type: Application
    Filed: March 29, 2018
    Publication date: July 14, 2022
    Inventors: Ho Young Song, Sung Min Kim, Hyoungrae Kim, Kyung Eun Park, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Su In Lee, Juyuel Baek, Hyeun J. Lee, Ju Y. Lee, Ji Hye Oh, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim
  • Patent number: 11173214
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: November 16, 2021
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Patent number: 11167040
    Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: November 9, 2021
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Publication number: 20200297865
    Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
    Type: Application
    Filed: November 23, 2016
    Publication date: September 24, 2020
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Publication number: 20190381185
    Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
    Type: Application
    Filed: November 23, 2016
    Publication date: December 19, 2019
    Applicant: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Publication number: 20190376979
    Abstract: The present invention relates to a method for constructing an Fv library based on a combination of proteins, a method of screening a desired antibody using the constructed Fv library, an Fv antibody screened by the screening method, and an Fv library constructed by the Fv library construction method. The Fv library of the present invention is based on a combination of proteins so that members thereof can be individually analyzed for their function. Moreover, the Fv library enables a desired Fv antibody to be screened without needing a target antigen preparation. In addition, the protein combination based Fv library makes it possible to significantly reduce the number of protein purification processes to thereby reduce costs and time, compared to conventional DNA-based libraries.
    Type: Application
    Filed: April 16, 2019
    Publication date: December 12, 2019
    Applicant: AbTLAS CO., LTD.
    Inventors: Byeong Doo SONG, Jee Sun YUN, Song Yi LEE, Hye In KIM, Hyo Jung CHOI, Jong Rip CHOI
  • Patent number: 10309969
    Abstract: The present invention relates to a method for constructing an Fv library based on a combination of proteins, a method of screening a desired antibody using the constructed Fv library, an Fv antibody screened by the screening method, and an Fv library constructed by the Fv library construction method. The Fv library of the present invention is based on a combination of proteins so that members thereof can be individually analyzed for their function. Moreover, the Fv library enables a desired Fv antibody to be screened without needing a target antigen preparation. In addition, the protein combination based Fv library makes it possible to significantly reduce the number of protein purification processes to thereby reduce costs and time, compared to conventional DNA-based libraries.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: June 4, 2019
    Assignee: AbTLAS CO., LTD.
    Inventors: Byeong Doo Song, Jee Sun Yun, Song Yi Lee, Hye In Kim, Hyo Jung Choi, Jong Rip Choi
  • Publication number: 20190151465
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.
    Type: Application
    Filed: November 23, 2016
    Publication date: May 23, 2019
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Publication number: 20190100749
    Abstract: The present invention relates to a method for prenatal diagnosis using digital PCR, and more particularly to a method for providing information for diagnosis of chromosomal aneuploidy in a fetus, comprising: (a) extracting DNAs from pregnant woman's blood; (b) classifying the DNAs according to size to obtain DNAs having a size of 1,000 bp or less; (c) performing digital PCR using the obtained DNAs of step (b), for a control gene located on a chromosome not associated with chromosomal aneuploidy and a target gene located on a chromosome associated with chromosomal aneuploidy; (d) calculating a ratio of a quantitative digital PCR value of the target gene to a quantitative digital PCR value of the control gene; and (e) determining that when the ratio calculated in step (d) is 0.70-1.14, a chromosome number of the fetus is normal.
    Type: Application
    Filed: October 28, 2016
    Publication date: April 4, 2019
    Inventors: Seung Yong Hwang, Moon Ju Oh, Seung Jun Kim, Jong Pil Youn, Ji Hoon Kim, Seung Yong Lee, Jeong Jin Ahn, Joon Soo Park, Hyo Jung Choi
  • Publication number: 20190077846
    Abstract: The present invention relates to a self-cleaving fusion protein including a target protein, a peptide consisting of amino acid sequence represented by LPXTG, a domain of Sortase A having cleaving function, and a tag, which are sequentially positioned from the amino terminal; a nucleic acid encoding the same; an expression vector including the nucleic acid of the present invention; and a cell transformed with the expression vector of the present invention. In addition, the present invention relates to a method for refining a target protein including culturing, dissolving, and purifying the transformed cell, and a method for preparing a therapeutic antibody-drug conjugate by using the purifying method.
    Type: Application
    Filed: August 9, 2018
    Publication date: March 14, 2019
    Applicant: AbTLAS CO., LTD.
    Inventors: Byeong Doo SONG, Jee Sun YUN, Hyo Jung CHOI, Hye In KIM, Eung-Suk LEE
  • Patent number: 10183997
    Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-CD19 antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: January 22, 2019
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yun Hee Park, Jeong Hee Ryu, Ho Young Song, Jeiwook Chae, Chul-Woong Chung, Ji Eun Jung, Hyo Jung Choi
  • Patent number: 10118965
    Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-epidermal growth factor receptor (“EGFR”) antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the drug; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: November 6, 2018
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yun Hee Park, Hyo Jung Choi, Ji Eun Jung, Jeong Hee Ryu, Ho Young Song, Jeiwook Chae, Chul-Woong Chung